BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25823974)

  • 1. RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases.
    Ushiku T; Ishikawa S; Kakiuchi M; Tanaka A; Katoh H; Aburatani H; Lauwers GY; Fukayama M
    Gastric Cancer; 2016 Apr; 19(2):403-411. PubMed ID: 25823974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes.
    Kwon CH; Kim YK; Lee S; Kim A; Park HJ; Choi Y; Won YJ; Park DY; Lauwers GY
    Histopathology; 2018 Mar; 72(4):556-568. PubMed ID: 28873240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RHOA mutations and CLDN18-ARHGAP fusions in intestinal-type adenocarcinoma with anastomosing glands of the stomach.
    Hashimoto T; Ogawa R; Tang TY; Yoshida H; Taniguchi H; Katai H; Oda I; Sekine S
    Mod Pathol; 2019 Apr; 32(4):568-575. PubMed ID: 30425335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers.
    Cho SY; Park JW; Liu Y; Park YS; Kim JH; Yang H; Um H; Ko WR; Lee BI; Kwon SY; Ryu SW; Kwon CH; Park DY; Lee JH; Lee SI; Song KS; Hur H; Han SU; Chang H; Kim SJ; Kim BS; Yook JH; Yoo MW; Kim BS; Lee IS; Kook MC; Thiessen N; He A; Stewart C; Dunford A; Kim J; Shih J; Saksena G; Cherniack AD; Schumacher S; Weiner AT; Rosenberg M; Getz G; Yang EG; Ryu MH; Bass AJ; Kim HK
    Gastroenterology; 2017 Aug; 153(2):536-549.e26. PubMed ID: 28522256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased RhoA Activity Predicts Worse Overall Survival in Patients Undergoing Surgical Resection for Lauren Diffuse-Type Gastric Adenocarcinoma.
    Chang KK; Cho SJ; Yoon C; Lee JH; Park DJ; Yoon SS
    Ann Surg Oncol; 2016 Dec; 23(13):4238-4246. PubMed ID: 27364501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort.
    Röcken C; Behrens HM; Böger C; Krüger S
    J Clin Pathol; 2016 Jan; 69(1):70-5. PubMed ID: 26251521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Correlation Between RhoA Expression and Clinicopathological Characteristics in Gastric Cancer Patients After Curative Surgery.
    Huang KH; Lan YT; Chen MH; Chao Y; Lo SS; Li AF; Wu CW; Chiou SH; Yang MH; Shyr YM; Fang WL
    World J Surg; 2015 Sep; 39(9):2289-99. PubMed ID: 26013205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of "regulation of RhoA activity panel" as a prognostic and predictive biomarker for gastric cancer.
    Huang W; Zhao S; Zhang C; Li Z; Ge S; Lian B; Feng H; Wang K; Xu R; Ji J; Gao J; Shi W; Shen L
    Aging (Albany NY); 2020 Dec; 13(1):714-734. PubMed ID: 33288739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential role of Wnt signaling and base excision repair pathways in gastric adenocarcinoma aggressiveness.
    Korourian A; Roudi R; Shariftabrizi A; Kalantari E; Sotoodeh K; Madjd Z
    Clin Exp Med; 2017 Nov; 17(4):505-517. PubMed ID: 27909884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo effects of mutant RHOA on tumor formation in an orthotopic inoculation model.
    Nishizawa T; Nakano K; Fujii E; Komura D; Kuroiwa Y; Ishimaru C; Monnai M; Aburatani H; Ishikawa S; Suzuki M
    Oncol Rep; 2019 Nov; 42(5):1745-1754. PubMed ID: 31485674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RhoA mutations identified in diffuse gastric cancer.
    Zhou J; Hayakawa Y; Wang TC; Bass AJ
    Cancer Cell; 2014 Jul; 26(1):9-11. PubMed ID: 25026207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenocarcinoma in the middle third of the stomach--an evaluation for the prognostic significance of clinicopathological features.
    Sheen-Chen SM; Chou CW; Chen MC; Chen FC; Chen YS; Chen JJ
    Hepatogastroenterology; 1997; 44(17):1488-94. PubMed ID: 9356878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma.
    Kakiuchi M; Nishizawa T; Ueda H; Gotoh K; Tanaka A; Hayashi A; Yamamoto S; Tatsuno K; Katoh H; Watanabe Y; Ichimura T; Ushiku T; Funahashi S; Tateishi K; Wada I; Shimizu N; Nomura S; Koike K; Seto Y; Fukayama M; Aburatani H; Ishikawa S
    Nat Genet; 2014 Jun; 46(6):583-7. PubMed ID: 24816255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults.
    Nakayama I; Shinozaki E; Sakata S; Yamamoto N; Fujisaki J; Muramatsu Y; Hirota T; Takeuchi K; Takahashi S; Yamaguchi K; Noda T
    Cancer Sci; 2019 Apr; 110(4):1352-1363. PubMed ID: 30771244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression and significance of RhoA and NF-ΚB in human gastric carcinoma].
    Su XJ; Tang ZF; Li Q; Li HL; Li LL; Liu M; Zhou YN
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):276-9. PubMed ID: 21575498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant alternative splicing of RHOA is associated with loss of its expression and activity in diffuse-type gastric carcinoma cells.
    Miyamoto S; Nagamura Y; Nakabo A; Okabe A; Yanagihara K; Fukami K; Sakai R; Yamaguchi H
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1942-1947. PubMed ID: 29247652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway.
    Lin MT; Lin BR; Chang CC; Chu CY; Su HJ; Chen ST; Jeng YM; Kuo ML
    Int J Cancer; 2007 Jun; 120(12):2600-8. PubMed ID: 17304514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain-of-Function
    Zhang H; Schaefer A; Wang Y; Hodge RG; Blake DR; Diehl JN; Papageorge AG; Stachler MD; Liao J; Zhou J; Wu Z; Akarca FG; de Klerk LK; Derks S; Pierobon M; Hoadley KA; Wang TC; Church G; Wong KK; Petricoin EF; Cox AD; Lowy DR; Der CJ; Bass AJ
    Cancer Discov; 2020 Feb; 10(2):288-305. PubMed ID: 31771969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.
    van der Post RS; Vogelaar IP; Manders P; van der Kolk LE; Cats A; van Hest LP; Sijmons R; Aalfs CM; Ausems MG; Gómez García EB; Wagner A; Hes FJ; Arts N; Mensenkamp AR; van Krieken JH; Hoogerbrugge N; Ligtenberg MJ
    Gastroenterology; 2015 Oct; 149(4):897-906.e19. PubMed ID: 26072394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced MUTYH, MTH1, and OGG1 expression and TP53 mutation in diffuse-type adenocarcinoma of gastric cardia.
    Kohno Y; Yamamoto H; Hirahashi M; Kumagae Y; Nakamura M; Oki E; Oda Y
    Hum Pathol; 2016 Jun; 52():145-52. PubMed ID: 26980051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.